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Isolation and Partial Purification of Hepatic 
Stimulatory Substance 
A. Francavilla, P. Ove, L. Polimeno, M. Coetzee, L. Makowka, M. Barone, 
D.H. Van Thiel, and T.E. Starzl 
THE PURPOSE of this study was to purify 
and characterize hepatic stimulatory 
substance (HSS), a protein found in the liver 
that has been reported to stimulate hepatic 
DNA synthesis and hepatocyte replication 
and that was previously identified by La-
Brecque et al l -3 and Francavilla et al in the rat 
liver,4,5 as well as by Starzl et al in the canine 
liver.6,7 
HSS has been partially purified by succes-
sive steps, involving ethanol precipitation, 
ultrafiltration, and fast protein lipid chroma-
tography (FPLC). The activity of this factor 
has been tested in 40% hepatectomized rats. 
MATERIALS AND METHODS 
Animals 
Male Fischer (F344) rats (180 to 200 g) and weanling 
Fischer (F344) rats (60 to 90 g), were purchased from 
Hilltop Lab Animals, Scottsdale, PA, and were kept in 
temperature and light controlled rooms. They received 
food and water ad libitum. 
Surgical Procedures 
Forty percent partial hepatectomies (PH) were per-
formed in rats according to Higgins and Anderson.s 
Control animals underwent a sham operation consisting 
of laparotomy and manual manipulation of the liver. 
Preparation of Hepatic Extracts 
In Table I, the preparation of HSS from liver cytosol is 
described. However, liver homogenates can also be used 
as the source of HSS as described by LaBrecque and 
Pesch' and US.6•7 
Sodium Dodecyl Sulfate (SDS) 
Polyacrylamide Gel Electrophoresis 
SOS polyacrylamide slab gels with a 7.5% to 20% 
gradient were prepared and developed according to 
Laemmli.9 Protein bands were visualized by Coomassie 
blue R 250 according to Weber and Osborn. lO 
Protein Determination 
Protein concentration was determined by the method of 
Lowry et al" or by the method of McKnight'2 for the 
determination of submicrogram quantities. 
Determination of the Activity of HSS 
and Its Fractions 
The activity of various fractions wa.s determined in vivo 
using 40% hepatectomized rats. Experiments were car-
ried out according to LaBrecque and Pesch.' ['HJ-
thymidine incorporation, labeling and mitotic indexes 
were determined as previously described." 
Statistical AnalysiS 
Statistical analysis of groups was carried out by one-
way analysis of variance using SPSS/PC statistical soft-
ware (SPSS, Inc, Chicago) on an IBM-AT microcomput-
er. 
RESULTS AND DISCUSSION 
Table 2 describes the purification steps of 
HSS and the physico-chemical characteristics 
of active fractions named Fl50 on the basis of 
its elution from the FPLC columns with MaCI 
at 150 mmol/L. 
HSS seems to be a protein with a molecular 
weight (MW) between 50 and 14 kd, which is 
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Table 1. Preparation and Purification of HSS 
Source 
Weanling male F-344 Fischer rats 
Purification steps 
Remove liver between 7 and a am 
Prepare cytosol as previously described 13 
Heat at 65 ° C for 15 minutes 
Centrifuge 30,000 g, at 4°C for 20 minutes 
Collect supernanant and add to 6 volumes of cold ethanol 
Stir for two hours at 4 ° C 
Centrifuge 37,000 g, at 4°C for 20 minutes 
Resuspend the pellet (OH-F) in NHA-acetate 
150 mmol/L, pH6.5 and homogenize 
Centrifuge 10,000 g, at 4°C forten minutes 
Filter the freshly prepared OH-F through 
Amicon PM30 ultrafiltration membrane 
Concentrate the PM30 filtrate using Amicon 
YC05 ultrafiltration membranes 
Lyophilize the concentrated material and keep 
at - 70°C (30 kd-F) 
Redissolve 30 kg-F in 5 mmol/L phosphate buffer for 
chromatography (FPLC using mono Q HR 5/5 column) 
Elute the active fraction (F'601 using a linear 
o to 200 mmol/L NaCI gradient at 150 mmol/L NaCI 
Dialyze F'60 in NH.-acetate, lyophilize and keep at -70°C 
resistant to neuraminidase, is destroyed by 
trypsin, and is resistant to heating at 95°C for 
ten minutes. The purification of F I50 results in 
a 38,000-fold increase of activity over the 
original cytosol. As previously described,14 
each preparation of Flso obtained from FPLC 
chromatography was completely free of recog-
nizable hormones such as insulin, glucagon, 
vasopressin, and EGF.14 The activity of each 
fraction during the various purification steps 
was tested in 40% hepatectomized rats. All 
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Fig 1. Dose response curve in 40% hepatectomized 
rats injected with F,60' DNA synthesis. percent of 
labeled nuclei. and percent of mitosis were determined 
as reported in Materials and Methods. The values 
shown are the averages of ten determinations for each 
level of F'60 ± SO and the average of four determina-
tions for each level of serum albumin in PBS ± SO .•• 
Significantly different from the control value PBS. P < 
.05. 
fractions demonstrated significantly more 
activity than PBS when injected into rats. 
The activity of Flso was dose-dependent 
over a range of 1.76 /Jog to 6.8 /Jog per 100 g 
body weight of the recipient rat. Thymidine 
incorporation results were confirmed by label-
ing and mitotic index results, as shown in 
Fig 1. 
Table 2. Steps of Purification of HSS and Chemical and Physico-Chemical Properties of Fraction F'60 Obtained 
From Weanling Rat Liver 
Protein 
Injected 
in Each Rat 
Material (mg/2 ml) 
Cytosol 75 
65°C Supernatant 20 
OH-F 10 
30kd 2_75 
F'60 0.003 
DNA 
Synthesis 
(cpm/mgF DNA)" Heat 
43,350 ± a,820t 
56,720 ± 10,240t 
66,350 ± 11 ,35Ot 
63,520 ± 13,22Ot 
54,380 ± 10,200 100% 
Resistant to 
Trypsin 
30% 
Neuro-
aminidase 
100% 
Purificaiton 
(Fold) 
6 
15 
102 
38,100 
.[3HJ-thymidine incorporation in a 40% hepatectomized rat injected with PBS was 16,500 cpm/mg DNA. The numbers are 
the averages from no less than 20 different rats ± SD. 
tSignificantly different from controls, P < .05. 
HEPATIC STIMULATORY SUBSTANCE 
It has been clearly demonstrated that F,so is 
organ, but not species specific.14 This fraction, 
as it presently exists, contains a few proteins, 
as indicated by SDS page with a MW ranging 
between 14 and 60 kd. Further studies are in 
process to obtain the final purification of 
HSS. Completely purified HSS would repre-
sent an important step in the knowledge of 
hepatocyte proliferation as well as in clinical 
therapy. 
The use of growth factor therapy for acute 
liver failure as well as in acute rejection after 
721 
liver transplantation in animals and in 
humans is, in fact, the main objective of this 
study. In fact, we have already shown that this 
type of therapy, using fractions obtained dur-
ing the HSS purification, significantly 
improves the survival rate of rats intoxicated 
with the selective hepatotoxin D-Galactos-
amineY 
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